Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IkT-001Pro in Pulmonary Arterial Hypertension
NCT06643143Phase 2Withdrawn
- Sponsor
- Inhibikase Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of IKT-001 in pulmonary arterial hypertension (PAH), sponsored by Inhibikase Therapeutics, Inc.. Planned start Jun 2025; status: withdrawn.
02
Drugs
IKT-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06643143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643143.